These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Potential microRNA targets for cancer chemotherapy. Tan S; Wu Y; Zhang CY; Li J Curr Med Chem; 2013; 20(29):3574-81. PubMed ID: 23834181 [TBL] [Abstract][Full Text] [Related]
45. The functional significance of microRNA-375 in human squamous cell carcinoma: aberrant expression and effects on cancer pathways. Kinoshita T; Hanazawa T; Nohata N; Okamoto Y; Seki N J Hum Genet; 2012 Sep; 57(9):556-63. PubMed ID: 22718022 [TBL] [Abstract][Full Text] [Related]
46. MicroRNAs and SerpinB3 in hepatocellular carcinoma. Turato C; Simonato D; Quarta S; Gatta A; Pontisso P Life Sci; 2014 Mar; 100(1):9-17. PubMed ID: 24496037 [TBL] [Abstract][Full Text] [Related]
47. MicroRNA-mediated autophagic signaling networks and cancer chemoresistance. Pan B; Yi J; Song H Cancer Biother Radiopharm; 2013 Oct; 28(8):573-8. PubMed ID: 23841710 [TBL] [Abstract][Full Text] [Related]
48. miR-214: a potential biomarker and therapeutic for different cancers. Sharma T; Hamilton R; Mandal CC Future Oncol; 2015; 11(2):349-63. PubMed ID: 25591843 [TBL] [Abstract][Full Text] [Related]
49. [miRNAs and cancer]. Jeanteur P Bull Cancer; 2010 Nov; 97(11):1231-9. PubMed ID: 21059489 [TBL] [Abstract][Full Text] [Related]
50. Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer. Fuse M; Kojima S; Enokida H; Chiyomaru T; Yoshino H; Nohata N; Kinoshita T; Sakamoto S; Naya Y; Nakagawa M; Ichikawa T; Seki N J Hum Genet; 2012 Nov; 57(11):691-9. PubMed ID: 22854542 [TBL] [Abstract][Full Text] [Related]
51. MicroRNAs as a new potential therapeutic opportunity in gastrointestinal cancer. Boni V; Bandres E; Zarate R; Colucci G; Maiello E; Garcia-Foncillas J Oncology; 2009; 77 Suppl 1():75-89. PubMed ID: 20130435 [TBL] [Abstract][Full Text] [Related]
52. MicroRNAs. Fabbri M; Croce CM; Calin GA Cancer J; 2008; 14(1):1-6. PubMed ID: 18303474 [TBL] [Abstract][Full Text] [Related]
53. The oncogenic RNA-binding protein Musashi1 is regulated by tumor suppressor miRNAs. Vo DT; Qiao M; Smith AD; Burns SC; Brenner AJ; Penalva LO RNA Biol; 2011; 8(5):817-28. PubMed ID: 21881409 [TBL] [Abstract][Full Text] [Related]
54. The role of miRNAs in cancer: from pathogenesis to therapeutic implications. Seven M; Karatas OF; Duz MB; Ozen M Future Oncol; 2014 May; 10(6):1027-48. PubMed ID: 24941988 [TBL] [Abstract][Full Text] [Related]
56. The Role of miR-21 in Cancer. Pfeffer SR; Yang CH; Pfeffer LM Drug Dev Res; 2015 Sep; 76(6):270-7. PubMed ID: 26082192 [TBL] [Abstract][Full Text] [Related]
57. MicroRNAs in DNA Damage Response, Carcinogenesis, and Chemoresistance. Fang Y; Zhang L; Li Z; Li Y; Huang C; Lu X Int Rev Cell Mol Biol; 2017; 333():1-49. PubMed ID: 28729023 [TBL] [Abstract][Full Text] [Related]
58. Recent patents on the identification and clinical application of microRNAs and target genes. Wang M; Xie H; Mi S; Chen J Recent Pat DNA Gene Seq; 2007; 1(2):116-24. PubMed ID: 19075924 [TBL] [Abstract][Full Text] [Related]
59. The roles of oncogenic miRNAs and their therapeutic importance in breast cancer. O'Bryan S; Dong S; Mathis JM; Alahari SK Eur J Cancer; 2017 Feb; 72():1-11. PubMed ID: 27997852 [TBL] [Abstract][Full Text] [Related]
60. Function of microRNA-143 in different signal pathways in cancer: New insights into cancer therapy. Karimi L; Mansoori B; Shanebandi D; Mohammadi A; Aghapour M; Baradaran B Biomed Pharmacother; 2017 Jul; 91():121-131. PubMed ID: 28448866 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]